Literature DB >> 11202060

Vascular remodeling in experimentally induced subacute canine pulmonary hypertension.

R Gust1, D P Schuster.   

Abstract

We quantified in vivo pulmonary vascular remodeling in a large animal model of pulmonary hypertension (PH). In group PH (n = 6), 3 mg/kg dehydromonocrotaline (DHMC) was administered to 12-week-old beagles via a right atrial injection. Eight weeks after DHMC in group PH, pulmonary artery pressure increased significantly (P < .05) from 18 +/- 2 mm Hg at baseline to 30 +/- 4 mm Hg. Medial wall thickness and medial wall area as a percentage of total vessel diameter or area was significantly higher (P < .05) in group PH (29 +/- 9% and 48 +/- 12%) than in a control group (n = 5) (7 +/- 1% and 14 +/- 1%). Neointimal proliferation was observed in 42% of pulmonary arterioles in the PH group but never in the control group. We conclude that a single injection of DHMC in young beagles, in addition to the development of moderate degrees of PH after 8 weeks, causes significant pulmonary vascular remodeling, with features similar to those observed in patients with primary PH.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11202060     DOI: 10.1080/019021401459734

Source DB:  PubMed          Journal:  Exp Lung Res        ISSN: 0190-2148            Impact factor:   2.459


  13 in total

1.  Idiopathic pulmonary arterial hypertension: an avian model for plexogenic arteriopathy and serotonergic vasoconstriction.

Authors:  Robert F Wideman; Krishna R Hamal
Journal:  J Pharmacol Toxicol Methods       Date:  2011-01-26       Impact factor: 1.950

2.  Hemodynamic and histologic characterization of a swine (Sus scrofa domestica) model of chronic pulmonary arterial hypertension.

Authors:  Abraham Rothman; Robert G Wiencek; Stephanie Davidson; William N Evans; Humberto Restrepo; Valeri Sarukhanov; Amanda Rivera-Begeman; David Mann
Journal:  Comp Med       Date:  2011-06       Impact factor: 0.982

3.  Differential modulation of right ventricular strain and right atrial mechanics in mild vs. severe pressure overload.

Authors:  Rochus K Voeller; Abdulhameed Aziz; Hersh S Maniar; Nneka N Ufere; Ajay K Taggar; Noel J Bernabe; Brian P Cupps; Marc R Moon
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-09-16       Impact factor: 4.733

Review 4.  Right Ventricular-Pulmonary Vascular Interactions.

Authors:  Diana M Tabima; Jennifer L Philip; Naomi C Chesler
Journal:  Physiology (Bethesda)       Date:  2017-09

Review 5.  Idiopathic pulmonary arterial hypertension.

Authors:  Amy L Firth; Jess Mandel; Jason X-J Yuan
Journal:  Dis Model Mech       Date:  2010 May-Jun       Impact factor: 5.758

6.  Differential calcium handling in two canine models of right ventricular pressure overload.

Authors:  Marc R Moon; Abdulhameed Aziz; Anson M Lee; Cynthia J Moon; Shoichi Okada; Evelyn M Kanter; Kathryn A Yamada
Journal:  J Surg Res       Date:  2012-05-17       Impact factor: 2.192

7.  Senescent endothelial progenitor cells from dogs with pulmonary arterial hypertension: a before-after self-controlled study.

Authors:  Liang Xia; Jun-hui Zhu; Fu-yu Qiu; Ying Yang; Xu-dong Xie; Xing-xiang Wang; Jun-zhu Chen; Guo-sheng Fu
Journal:  J Physiol Sci       Date:  2009-07-28       Impact factor: 2.781

8.  Carbonic anhydrase inhibition improves pulmonary artery reactivity and nitric oxide-mediated relaxation in sugen-hypoxia model of pulmonary hypertension.

Authors:  Helen Christou; Zoe Michael; Fotios Spyropoulos; Yunfei Chen; Dan Rong; Raouf A Khalil
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2021-04-07       Impact factor: 3.210

9.  In vivo and in vitro measurements of pulmonary arterial stiffness: A brief review.

Authors:  Lian Tian; Naomi C Chesler
Journal:  Pulm Circ       Date:  2012-10       Impact factor: 3.017

10.  Experimental animal models of pulmonary hypertension: Development and challenges.

Authors:  Xiao-Han Wu; Jie-Ling Ma; Dong Ding; Yue-Jiao Ma; Yun-Peng Wei; Zhi-Cheng Jing
Journal:  Animal Model Exp Med       Date:  2022-03-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.